The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

The treatment for COVID-19 has evolved rapidly since the start of the pandemic and now
consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir …

Abstract The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and
escape of vaccine-derived immunity. Although first-generation vaccines remain effective …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Nirmatrelvir–ritonavir (Paxlovid [Pfizer]) is used as first-line therapy for nonhospitalized
persons with Covid-191 on the basis of the results of the Evaluation of Protease Inhibition for …

Background: COVID-19 has been linked to the development of many post–COVID-19
conditions (PCCs) after acute infection. Limited information is available on the effectiveness …

Importance Several pharmacotherapies have been authorized to treat nonhospitalized
persons with symptomatic COVID-19. Longitudinal information on the use of these therapies …

Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …